Samsung Bioepis’s Biosimilar Trastuzumab First To Take On Roche’s Herceptin In EU
Samsung Bioepis’s Ontruzant is likely to be the first biosimilar to take on Roche’s Herceptin in the EU market after it was recommended for marketing authorization by the EMA’s CHMP on Sept 15.
You may also be interested in...
More Questions As Biocon Pulls EU Filings For Two Biosimilars
Biocon and partner Mylan have withdrawn the European application for their biosimilar trastuzumab and pegfilgrastim in the backdrop of compliance blips at Biocon’s Indian site, raising critical questions on how soon things can be set right in an increasingly competitive scenario.
Canada Proposes List Of ‘Critical Products’ & More Agile Regulation To Address Shortages
The Canadian government says stakeholders are “poised for action” to improve the collective response to drug shortages and has come up with some questions and possible answers as to how best to go about it.
What Would An EU ‘Regulatory Sandbox’ Bring To New Drug Development?
Digital health, AI, real-world evidence and “proactive learning” are key components of the EU’s proposals for new ways of regulating novel medicines, but only time will tell which products might benefit from the flexibilities offered by the “regulatory sandbox.”